Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorContextVision AB

About this trial

The research study is considering a non-invasive way to measure the percentage of fat in the liver using ultrasound. This could help detect early signs of a very common condition called metabolic dysfunction-associated steatotic liver disease (MASLD). Current tests, like MRI or biopsy, can be expensive or invasive. If successful, this ultrasound tool could become an easier and more accessible way to monitor liver health - especially for people with obesity, diabetes, high blood pressure, or high cholesterol.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Adult patients (age 18 - 75 years)

Consent to participate in the study

Diagnosed or suspected MASLD from the hepatology clinic, OR

High-risk population meeting the adult cardiometabolic criteria (defined as the presence of at least one of the following: diabetes, obesity (BMI ≥ 25 kg/m2), hypercholesterolemia, and hypertension)

Disqualifiers

Pregnancy or nursing.

Contraindications to MRI including, but not limited to, severe claustrophobia, pacemaker, or existing metallic/mechanical implant(s).

Acute illness/cognitive impairment resulting in an inability to cooperate with the MRI and ultrasound breath-holding instructions.

BMI > 35 kg/m2

Trial design

Design model

Single group

Treatments tested in this trial

  • Verasonics NXT Data Acquisition System

    Device

    A research ultrasound imaging device to capture raw radiofrequency ultrasound data for the following parameters: * B-mode imaging * Attenuation coefficient * Backscatter coefficient * Speed of sound * Shear wave elastography

  • Philips EPIQ Elite

    Device

    A premium ultrasound system with software package to support imaging research studies.

  • EchoSense FibroScan

    Device

    A non-invasive ultrasound solution that accurately measures liver stiffness and liver steatosis.

  • Philips 3T Ingenia Elition

    Device

    A 3-tesla magnetic resonance imaging (MRI) system

Treatment groups

110 Participants
are divided into 1 treatment group
Group A: CohortExperimental treatment 4 interventions

Trial outcomes

Primary outcomes

1

Multiparametric Ultrasound Biomarker vs. MR-PDFF

Clinical qualification of the multiparametric ultrasound-derived fat fraction, defined as its agreement with the established clinical reference, MRI proton density fat fraction (MRI-PDFF) expressed as absolute percentage, in bench testing analysis.

Time frame
1 year

Secondary outcomes

1

Individual Ultrasound parameter vs. MRI-PDFF

Evaluation of each ultrasound parameter (backscatter, attenuation and speed of sound) fat percentage values separately against MRI-PDFF.

Time frame
1 year
2

Ultrasound Shear Wave vs MR Elastography

Evaluation of ultrasound shear wave elastography-derived tissue stiffness values in kilopascals compared to MR elastography.

Time frame
1 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

ContextVision AB

Lead sponsor

University of Washington

Collaborator